多omics分析描述了与黑色素瘤细胞中BRAF抑制相关的抵抗机制
Keshava K Datta1, Hitesh Kore2, Harsha Gowda3
1Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Experimental cell research
|August 25, 2024
概括
了解黑色素瘤中BRAF抑制剂耐药性的关键是. 这项研究在细胞模型中使用了多种omics来揭示耐药性机制,并确定黑色素瘤治疗的新治疗点.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 生物化学 生化学
背景情况:
- 突变BRAF驱动黑色素瘤,使得BRAF抑制剂 (BRAFi) 成为一种关键疗法.
- 对BRAFi的耐药性,如维穆拉芬尼和达布拉芬尼,限制了治疗的有效性.
- 了解抵抗机制对于开发更有效的癌症药物至关重要.
研究的目的:
- 用体外模型来描述黑色素瘤中BRAF抑制剂耐药性机制.
- 为了确定克服BRAFi耐药性的新型治疗点.
- 验证体外系统对预测耐药性和发现药物点的有用性.
主要方法:
- 采用了多omics方法,包括外体序列,蛋白质组学和光蛋白质组学.
- 开发并表征了BRAFi持久性和耐性黑色素瘤细胞系.
- 分析了遗传和非遗传抵抗机制.
主要成果:
- 确定了BRAFi耐药性的共同内在和获得的遗传和非遗传机制.
- 揭示了体外耐药机制与在患者中观察到的机制之间的相似之处.
- 发现了克服BRAFi耐药性的潜在蛋白质标.
结论:
- 在体外细胞模型对于研究和预测黑色素瘤中BRAF抑制剂耐药性是有效的.
- 这项研究确定了可操作的治疗点,以克服BRAFi耐药性.
- 这些发现为改善BRAF突变黑色素瘤治疗的临床结果铺平了道路.
更多相关视频
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
2.9K
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
6.0K
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
